Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma

PURPOSE: Intraventricular compartmental radioimmunotherapy (cRIT) with 131-I-omburtamab is a potential therapy for recurrent primary brain tumors that can seed the thecal space. These patients often previously received external beam radiotherapy (EBRT) to a portion or full craniospinal axis (CSI) as...

Descripción completa

Detalles Bibliográficos
Autores principales: Tringale, Kathryn R., Wolden, Suzanne L., Karajannis, Matthias, Haque, Sofia, Pasquini, Luca, Yildirim, Onur, Rosenblum, Marc, Benhamida, Jamal K., Cheung, Nai-Kong, Souweidane, Mark, Basu, Ellen M., Pandit-Taskar, Neeta, Zanzonico, Pat B., Humm, John L., Kramer, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050019/
https://www.ncbi.nlm.nih.gov/pubmed/36853490
http://dx.doi.org/10.1007/s11060-022-04235-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050019/
https://www.ncbi.nlm.nih.gov/pubmed/36853490
http://dx.doi.org/10.1007/s11060-022-04235-w

Ejemplares similares